iDTECT® Integration Site Analysis assay: a paradigm shift for the quality control of biologics in rare diseases

Abstract

A landmark collaboration between Oxford Nanopore Technologies and PathoQuest sets a groundbreaking precedent and paradigm shift in the field of biopharmaceuticals — particularly in the niche area of rare diseases. Through the combination of advanced nanopore-based sequencing capabilities and PathoQuest’s exquisite, targeted genomic (integration site) characterization methodology, this iDTECT® Integration Site Analysis assay not only promises to streamline the approval process for these vital therapies but also significantly improves the treatment landscape for rare disease patients. By providing a compelling example of this strategy, this collaboration illustrates the tangible benefits of combining cutting-edge genomic technologies with stringent quality control measures, marking a leap forward in the future of biopharmaceuticals.

Biography

Crispin joined PathoQuest in 2023 as the R&D Project Leader, focused on designing and developing novel next generation sequencing-based applications for the biosafety testing industry. Crispin earned his PhD in Infectious Microbiology from Institut Pasteur & Universite de Paris, France, where he applied his molecular and cellular biology skills to understand the mechanisms behind infectious diseases. Prior to joining PathoQuest, he previously held the positions of Research Scientist at Evotec, focusing on drug development, and as a Research Professor at the Autonomous University of the State of Morelos Mexico (UAEM) where he earned his bachelor’s degree.